VNDA

Vanda Pharmaceuticals Inc. (VNDA) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its commercial portfolio consists of three products: Fanapt (iloperidone) for bipolar I disorder and schizophrenia; HETLIOZ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome; and PONVORY (ponesimod) for relapsing forms of multiple sclerosis.

Key Financial Metrics

Note: The filing does not explicitly state gross margin percentages; however, Cost of Goods Sold for Q3 2025 was $3.0 million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 18% in Q3 2025 and 9% for the nine months ended September 30, 2025, compared to the prior year periods.
• Product Performance:
  • Fanapt: Sales increased 31% in Q3 and 24% for the nine months, driven by volume growth following the commercial launch for bipolar I disorder in Q3 2024.
  • HETLIOZ: Sales were flat in Q3 (+1%) but declined 3% for the nine months due to volume decreases and generic competition.
  • PONVORY: Sales increased 20% in Q3 but declined 7% for the nine months, attributed to price net of deductions.
• Expense Increases:
  • R&D Expenses: Increased 34% in Q3 and 47% for the nine months. The nine-month increase was significantly driven by a $15.0 million upfront payment for the global license of imsidolimab from AnaptysBio.
  • Selling, General & Administrative (SG&A): Increased 60% in Q3 and 63% for the nine months due to expanded commercial activities and marketing for Fanapt and PONVORY.
• Liquidity: Cash, cash equivalents, and marketable securities decreased from $374.6 million at year-end 2024 to $293.8 million as of September 30, 2025.

Guidance, Outlook, and Risks

• Regulatory & Clinical Updates:
  • FDA Agreement: On October 1, 2025, Vanda agreed to a collaborative framework with the FDA to resolve disputes regarding HETLIOZ and tradipitant. This includes expedited re-reviews for tradipitant (motion sickness) and HETLIOZ (jet lag disorder).
  • Bysanti: NDA for bipolar I disorder and schizophrenia is under review with a PDUFA date of February 21, 2026.
  • Tradipitant: NDA for motion sickness has a PDUFA date of December 30, 2025.
  • Imsidolimab: Biologics License Application (BLA) for generalized pustular psoriasis is expected to be submitted in Q4 2025.
• Legal Proceedings: The company is engaged in extensive litigation regarding patent infringement and FDA approvals, primarily concerning generic versions of HETLIOZ (Teva, Apotex, MSN) and regulatory disputes with the FDA regarding tradipitant and HETLIOZ indications.
• Risks: Key risks include the impact of generic competition on HETLIOZ, the success of commercial launches for Fanapt and PONVORY, reimbursement challenges, and the outcome of ongoing litigation and regulatory reviews.

Investor Verification Checklist

• Imidolimab License: Verify the impact of the $15.0 million upfront payment on R&D expenses and future milestone obligations.
• HETLIOZ Generic Competition: Monitor the status of patent litigation against Teva, Apotex, and MSN, and the potential impact on future revenue given the constrained revenue recognition due to inventory stocking uncertainties.
• FDA Collaborative Framework: Track the outcomes of the expedited re-reviews for tradipitant and HETLIOZ jet lag indication agreed upon in October 2025.
• Cash Burn Rate: Assess the sustainability of the current cash position ($293.8 million) given the significant increase in operating cash burn ($80.0 million used in 9M 2025).
• Commercial Launch Execution: Evaluate the sustainability of Fanapt's 31% Q3 growth and PONVORY's volume trends amidst price net of deductions.